Nyrada Inc. Appendix 4D Half-year report
Half yearly Results and Appendix 4D
Nyrada Half Year FY2025 Results
Highlights: •Development of lead drug candidate NYR-BI03 continues: -Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia-reperfusion injury. -Phase… Read more
Nyrada to Commence Phase Ia Clinical Trial
Highlights: •Nyrada receives Human Research Ethics Committee (HREC) approval to initiate first-in-human Phase Ia clinical trial. •Trial will evaluate the… Read more
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Development of lead drug candidate NYR-BI03 continues to advance: -Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia… Read more
NYR-BI03 Phase Ia Clinical Trial Update 2
Highlights: •Nyrada’s Phase Ia Clinical Trial regulatory package has been submitted to Human Research Ethics Committee (HREC). •HREC review expected… Read more
Nyrada Receives A$1.235M R&D Tax Incentive Rebate
Nyrada Inc (ASX:NYR), a drug discovery and development company focused on innovative Transient Receptor Potential Canonical (TRPC) ion channel blockers… Read more
Nyrada -NYR-BI03 Phase Ia Clinical Trial Update – Correction
Highlights: •Nyrada is scheduled to submit its regulatory package to Human Research Ethics Committee (HREC) for review before the end… Read more
Nyrada Investor presentation
Investor Presentation November 2024 Improving Lives, Offering Hope
Nyrada AGM Presentation -James Bonnar CEO
Summary ›Pioneering transient receptor potential canonical (TRPC) channel blocking therapies. ›First-in-class neuroprotection and cardioprotection therapy with novel mode of action…. Read more